secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eiger BioPharmaceuticals, Inc. (—)
CIK:        0001305253
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001193125-24-134319
Event type: m_and_a
Sentiment:  negative
Materiality: 0.90
Item codes: 2.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Eiger sells Zokinvy global rights to Sentynl for $45.2M net in bankruptcy sale
------------------------------------------------------------------------------

- Closed sale of Zokinvy (lonafarnib) worldwide rights to Sentynl Therapeutics; net base price $45.2M after $0.9M credit.
- Bankruptcy Court approved sale on April 23; deal closed May 3, 2024.
- Sentynl assumes manufacture and commercialization of Zokinvy.
- Company cautions securityholders that trading is highly speculative; holders may face significant or complete loss.
- During Chapter 11, Eiger will file monthly financial reports with SEC instead of 10-K/10-Q.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524134319/0001193125-24-134319-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524134319/d834255d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-134319

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer